ACADIA Pharmaceuticals Inc.
ACAD
Price:
$16.07
Market Cap:
$2.67B
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for...[Read more]
Industry
Biotechnology
IPO Date
2004-05-27
Stock Exchange
NASDAQ
Ticker
ACAD
The ROE as of September 2024 (TTM) for ACADIA Pharmaceuticals Inc. (ACAD) is 6.89%
According to ACADIA Pharmaceuticals Inc.’s latest financial reports and current stock price. The company's current ROE is 6.89%. This represents a change of 943.45% compared to the average of 0.66% of the last 4 quarters.
ACADIA Pharmaceuticals Inc. (ACAD) Historical ROE (quarterly & annually)
How has ACAD ROE performed in the past?
The mean historical ROE of ACADIA Pharmaceuticals Inc. over the last ten years is -47.98%. The current 6.89% ROE has changed -114.36% with respect to the historical average. Over the past ten years (40 quarters), ACAD's ROE was at its highest in in the December 2023 quarter at 10.61%. The ROE was at its lowest in in the September 2018 quarter at -27.81%.
Average
-47.98%
Median
-48.04%
Minimum
-86.32%
Maximum
-14.19%
ACADIA Pharmaceuticals Inc. (ACAD) ROE by Quarter and Year
Discovering the peaks and valleys of ACADIA Pharmaceuticals Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 175.50%
Maximum Annual ROE = -14.19%
Minimum Annual Increase = -73.68%
Minimum Annual ROE = -86.32%
| Year | ROE | Change |
|---|---|---|
| 2023 | -14.19% | -73.68% |
| 2022 | -53.94% | 73.79% |
| 2021 | -31.04% | -30.89% |
| 2020 | -44.91% | 33.46% |
| 2019 | -33.65% | -34.25% |
| 2018 | -51.18% | -40.71% |
| 2017 | -86.32% | 64.88% |
| 2016 | -52.35% | -36.41% |
| 2015 | -82.32% | 175.50% |
| 2014 | -29.88% | 43.41% |
ACADIA Pharmaceuticals Inc. (ACAD) Average ROE
How has ACAD ROE performed in the past?
The current ROE of ACADIA Pharmaceuticals Inc. (ACAD) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-33.06%
5-year avg
-35.55%
10-year avg
-47.98%
ACADIA Pharmaceuticals Inc. (ACAD) ROE vs. Peers
How is ACAD’s ROE compared to its peers?
ACADIA Pharmaceuticals Inc.’s ROE is greater than Madrigal Pharmaceuticals, Inc. (-95.61%), greater than Viking Therapeutics, Inc. (-15.05%), less than Sarepta Therapeutics, Inc. (5.17%), greater than Hepion Pharmaceuticals, Inc. (-328.66%), less than PTC Therapeutics, Inc. (57.03%), less than Reviva Pharmaceuticals Holdings, Inc. (7.96%), greater than Athira Pharma, Inc. (-95.53%), greater than Fortress Biotech, Inc. (-226.63%), greater than Cabaletta Bio, Inc. (-43.98%), greater than Intercept Pharmaceuticals, Inc. (-78.24%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Akero Therapeutics, Inc. (-29.56%), less than Reata Pharmaceuticals, Inc. (19.32%), less than Krystal Biotech, Inc. (13.36%), greater than Blueprint Medicines Corporation (-85.25%),
| Company | ROE | Market cap |
|---|---|---|
| -95.61% | $5.30B | |
| -15.05% | $6.00B | |
| 5.17% | $12.29B | |
| -328.66% | $4.20M | |
| 57.03% | $2.43B | |
| 7.96% | $44.68M | |
| -95.53% | $20.81M | |
| -226.63% | $40.38M | |
| -43.98% | $208.10M | |
| -78.24% | $794.69M | |
| -39.58% | $549.60M | |
| -29.56% | $1.83B | |
| 19.32% | $6.57B | |
| 13.36% | $5.29B | |
| -85.25% | $5.47B |
Build a custom stock screener for ACADIA Pharmaceuticals Inc. (ACAD) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ACADIA Pharmaceuticals Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
ACADIA Pharmaceuticals Inc. (ACAD) and other stocks custom spreadsheet templates
The easiest way to analyze a company like ACADIA Pharmaceuticals Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is ACADIA Pharmaceuticals Inc.'s ROE?
How is the ROE calculated for ACADIA Pharmaceuticals Inc. (ACAD)?
What is the highest ROE for ACADIA Pharmaceuticals Inc. (ACAD)?
What is the 3-year average ROE for ACADIA Pharmaceuticals Inc. (ACAD)?
What is the 5-year average ROE for ACADIA Pharmaceuticals Inc. (ACAD)?
How does the current ROE for ACADIA Pharmaceuticals Inc. (ACAD) compare to its historical average?